Antonio Mazzocca

List of Publications by Year
in descending order

33 papers	833 citations	471509 17 h-index	501196 28 g-index
34 all docs	34 docs citations	34 times ranked	1149 citing authors

#	Article	IF	Citations
1	Chronic Inflammation in Obesity and Cancer Cachexia. Journal of Clinical Medicine, 2022, 11, 2191.	2.4	10
2	The Edible Plant Crithmum maritimum Shows Nutraceutical Properties by Targeting Energy Metabolism in Hepatic Cancer. Plant Foods for Human Nutrition, 2022, 77, 481-483.	3.2	7
3	Translational insight into prothrombotic state and hypercoagulation in nonalcoholic fatty liver disease. Thrombosis Research, 2021, 198, 139-150.	1.7	27
4	1H-NMR metabolomics reveals a multitarget action of Crithmum maritimum ethyl acetate extract in inhibiting hepatocellular carcinoma cell growth. Scientific Reports, 2021, 11, 1259.	3.3	19
5	DNA Damage Response Protein CHK2 Regulates Metabolism in Liver Cancer. Cancer Research, 2021, 81, 2861-2873.	0.9	15
6	Treatment of liver cancer cells with ethyl acetate extract of Crithmum maritimum permits reducing sorafenib dose and toxicity maintaining its efficacy. Journal of Pharmacy and Pharmacology, 2021, 73, 1369-1376.	2.4	16
7	Xanthenylacetic Acid Derivatives Effectively Target Lysophosphatidic Acid Receptor 6 to Inhibit Hepatocellular Carcinoma Cell Growth. ChemMedChem, 2021, 16, 2121-2129.	3.2	9
8	New hypotheses for cancer generation and progression. Medical Hypotheses, 2021, 152, 110614.	1.5	4
9	Autotaxin impedes anti-tumor immunity by suppressing chemotaxis and tumor infiltration of CD8+ TÂcells. Cell Reports, 2021, 37, 110013.	6.4	38
10	Novel lysophosphatidic acid receptor 6 antagonists inhibit hepatocellular carcinoma growth through affecting mitochondrial function. Journal of Molecular Medicine, 2020, 98, 179-191.	3.9	22
11	Inhibition of Hepatocellular Carcinoma Growth by Ethyl Acetate Extracts of Apulian Brassica oleracea L. and Crithmum maritimum L.. Plant Foods for Human Nutrition, 2020, 75, 33-40.	3.2	18
12	The perplexity of targeting genetic alterations in hepatocellular carcinoma. Medical Oncology, 2020, 37, 67.	2.5	1
13	A distinctive protein signature induced by lysophosphatidic acid receptor 6 (LPAR6) expression in hepatocellular carcinoma cells. Biochemical and Biophysical Research Communications, 2020, 526, 1150-1156.	2.1	5
14	The Systemicâ€"Evolutionary Theory of the Origin of Cancer (SETOC): A New Interpretative Model of Cancer as a Complex Biological System. International Journal of Molecular Sciences, 2019, 20, 4885.	4.1	22
15	Circadian rhythms: a possible new player in non-alcoholic fatty liver disease pathophysiology. Journal of Molecular Medicine, 2019, 97, 741-759.	3.9	18
16	Emerging metabolic risk factors in hepatocellular carcinoma and their influence on the liver microenvironment. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2018, 1864, 607-617.	3.8	41
17	Moving the systemic evolutionary approach to cancer forward: Therapeutic implications. Medical Hypotheses, 2018, 121, 80-87.	1.5	13
18	Autotaxin is a novel molecular identifier of type I endometrial cancer. Medical Oncology, 2018, 35, 157.	2.5	8

#	Article	IF	Citations
19	New molecular targets for functionalized nanosized drug delivery systems in personalized therapy for hepatocellular carcinoma. Journal of Controlled Release, 2017, 268, 184-197.	9.9	33
20	Implications of the lysophosphatidic acid signaling axis in liver cancer. Biochimica Et Biophysica Acta: Reviews on Cancer, 2017, 1868, 277-282.	7.4	23
21	Hepatocellular Carcinoma as a Paradigm for a Systemic Evolutionary Approach to Cancer. , 2016, , 157-161.		1
22	A systemic evolutionary approach to cancer: Hepatocarcinogenesis as a paradigm. Medical Hypotheses, 2016, 93, 132-137.	1.5	13
23	Metastatic Secondary Anaplastic Meningioma. Open Access Library Journal (oalib), 2016, 03, 1-6.	0.2	0
24	Sorafenib: 10 years after the first pivotal trial. Future Oncology, 2015, 11, 1863-1880.	2.4	40
25	Lysophosphatidic Acid Receptor LPAR6 Supports the Tumorigenicity of Hepatocellular Carcinoma. Cancer Research, 2015, 75, 532-543.	0.9	49
26	Sorafenib: the gold standard therapy in advanced hepatocellular carcinoma and beyond. Future Oncology, 2015, 11, 2263-2266.	2.4	17
27	Reply. Hepatology, 2013, 57, 418-419.	7.3	1
28	Abstract 4217: Engaging CD151 inhibits cell migration and metastasis through a novel mechanism involving the cell adhesion molecule ALCAM/CD166. , 2012, , .		0
29	Tumor-secreted lysophostatidic acid accelerates hepatocellular carcinoma progression by promoting differentiation of peritumoral fibroblasts in myofibroblasts. Hepatology, 2011, 54, 920-930.	7.3	122
30	The Metastatic Process: Methodological Advances and Pharmacological Challenges. Current Medicinal Chemistry, 2009, 16, 1704-1717.	2.4	33
31	Tissue expression of Squamous Cellular Carcinoma Antigen (SCCA) is inversely correlated to tumor size in HCC. Molecular Cancer, 2009, 8, 29.	19.2	28
32	Growth Inhibition by the Farnesyltransferase Inhibitor FTI-277 Involves Bcl-2 Expression and Defective Association with Raf-1 in Liver Cancer Cell Lines. Molecular Pharmacology, 2003, 63, 159-166.	2.3	18
33	T(14;18) translocation in chronic hepatitis C virus infection. Hepatology, 2000, 31, 474-479.	7.3	157